THE pancreatic cancerthis “silent killer” most often diagnosed late, when the tumor has grown outside the pancreas, is the 9th most common cancer in men and the 7th most common cancer in the woman.
Due to its late diagnosis, pancreatic cancer is particularly lethal. This is why the announcement by the BioNTech laboratory of a messenger RNA vaccine that would reduce the risk of recurrence in patients with pancreatic cancer is particularly hopeful.
A vaccine tested on 16 patients
In a published study in Nature magazine, the researchers highlight the good results of a clinical trial based on messenger RNA, already used for the vaccine against Covid-19. This vaccine candidate was tested on 16 patients suffering from a virulent form of pancreatic cancer, 9 weeks after removal of their tumour.
A pancreatic cancer vaccine provoked an immune response in half of the patients treated, and those people showed no relapse of their cancer during the course of the study, a finding that outside experts described as extremely promising. https://t.co/JTRR7mvpr3
— The New York Times (@nytimes) May 12, 2023
The messenger RNA vaccine elicited an immune response in half of the patients treated, who suffered no recurrence of their cancer during the roughly 18 months they were followed. In patients who appeared to be unresponsive to the vaccine, the tumor reappeared about 13 months after the operation.
Source : Vaccine boosts T cells that target pancreatic tumorsNature, May 2023
GIPHY App Key not set. Please check settings